Atara Biotherapeutics (NASDAQ:ATRA) Lowered to Hold Rating by RODMAN&RENSHAW

Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by analysts at RODMAN&RENSHAW from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other brokerages have also weighed in on ATRA. Canaccord Genuity Group cut their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, January 17th. Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 target price for the company. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday. One analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Stock Up 13.9 %

Shares of Atara Biotherapeutics stock opened at $6.89 on Tuesday. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $39.50. The business has a fifty day simple moving average of $12.16 and a 200 day simple moving average of $9.97. The stock has a market cap of $39.69 million, a PE ratio of -0.27 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same period in the prior year, the business earned ($16.50) earnings per share. Analysts expect that Atara Biotherapeutics will post -9.86 EPS for the current fiscal year.

Institutional Trading of Atara Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new position in Atara Biotherapeutics in the second quarter valued at approximately $79,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Atara Biotherapeutics in the 2nd quarter valued at approximately $53,000. FMR LLC grew its stake in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares in the last quarter. Vestal Point Capital LP increased its holdings in Atara Biotherapeutics by 11.3% during the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 12,677 shares during the last quarter. Finally, State Street Corp raised its position in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares in the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.